Ohr Pharmaceutical to Report Third Quarter 2015 Financial and Business Results on Thursday, August 6

NEW YORK, July 30, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the third quarter ended June 30, 2015 after the market close on Thursday, August 6 2015. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern.

Conference Call & Webcast
Thursday, August 6, 2015 at 5:00pm Eastern Time/2:00pm Pacific Time
Domestic: 888-296-4215
International: 719-325-2447
Conference ID: 6561903
Webcast: http://public.viavid.com/player/index.php?id=115690
Replays – Available through August 20, 2015
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 6561903

About Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. is an ophthalmology research and development company whose lead product, Squalamine, is being studied as an eye drop formulation (OHR-102) in several company-sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases. These diseases include wet-AMD, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.

CONTACT: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 ir@ohrpharmaceutical.com LifeSci Advisors, LLC Michael Wood 646-597-6983 mwood@lifesciadvisors.comSource:Ohr Pharmaceutical, Inc.